-
-
Exactly 1397 antiretroviral (ARV) naïve patients initiating ARVs, as part of a CPCRA-sponsored clinical trial (FIRST trial), were followed for a median of five years.
-
The utility of surveillance screening for MRSA on hospital admission remains controversial. Three recently published clinical trials attempt to assess the role of MRSA surveillance.
-
All patients admitted to the ICU at the Air Force Theater Hospital (Balad, Iraq) were followed prospectively for the development of VAP. There were 475 patients admitted to the ICU from May 2006 through August 2006.
-
-
In this Issue: Pioglitazone and heart disease; ARBs manufacturers spend millions to show the non-inferiority of their products compared to less expensive, generic ACE inhibitors; some athletes turn to growth hormone because it is difficult to detect; FDA Actions
-
Pioglitazone and heart disease; ARBs manufacturers spend millions to show the non-inferiority of their products compared to less expensive, generic ACE inhibitors; some athletes turn to growth hormone because it is difficult to detect; FDA Actions
-
Most of us dread the chief complaint of weakness. This nonspecific symptom engenders a differential that ranges from malingering to fatal, from psychiatric to cancer. The finding of demonstrable muscle weakness helps, but then leads to a confusing set of relatively rare diagnoses.
-
-
Lifestyle changes such as improving diet and exercise are always the first important approach for the treatment of hyperlipidemia however, if the target LDL-C level is not achieved using statins and niacin, fibrates, and/or resins, at this time, ezetimibe should definitely be utilized to achieve these target goals if there are no specific contraindications to the use of the drug in each individual patient.
